FTC shows an interest
Executive Summary
Federal Trade Commission filed a "friend of the court" brief in the Bristol/ABI/Ivax case indicating that the agency is investigating the terms of Bristol's licensing agreement for the ABI patent. The patent, covering a Cremophor-free formulation of paclitaxel, was listed by Bristol in mid-August (1"The Pink Sheet" Aug. 21, p. 3)
You may also be interested in...
Bristol Taxol Exclusivity Continues, Thanks To ABI Cremophor-Free Patent
Bristol-Myers Squibb's latest extension to the exclusivity for Taxol depends on continued rulings against the company in patent litigation in the Los Angeles federal court.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials